18 Norsteroids as selectively active estrogens

US6958327B1 · kind B1 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Alexander Hillisch · Solingen, DE
• Werner Boidol · Berlin, DE
• Wolfgang Schwede · Berlin, DE
• Peter Esperling · Berlin, DE
• Gerhard Sauer · Berlin, DE
• Christa Hegele-Hartung · Neheim, DE
• Uwe Kollenkirchen · Berlin, DE
• Karl-Heinrich Fritzemeier · Berlin, DE

Key dates

• Filing date: Nov 2, 2000
• Grant date: Oct 25, 2005
• Expiry date: Nov 2, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J1/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R1, R2, R3, R6, R7, R8, R9, R11, R11′, R14, R15, R15′, R16, R17 and R17′ have the meaning cited in the description, and to the use of said compounds as pharmaceutical active ingredients. Said compounds exhibit a high affinity in vitro for estrogen receptor preparations of rat prostate and in an estrogen receptor preparation of rat uterus. Said compounds exhibit in vivo preferential activity on bones as compared to the uterus and/or significant activity with regard to stimulating the expression of 5HT2a-receptors and transporter molecules. The invention also relates to the production of said compounds, therapeutic use and galenic form of said compounds contained in the novel compounds of invention. The invention also relates to utilization of steroids based on the gonatriene molecular skeleton in order to treat estrogen deficiency-induced diseases and disorders, in addition to the use of said gonatriene structural component in the total structure of compounds which dissociate to produce enhanced estrogen activity in bone as compared to the uterus